Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASPH | Q12797 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.36 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 2/20 | 0.35 |
| ▸ | JUN | P05412 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30505631 | 1.00 | ASPH (0.38) | ASPHKDM4EALOX15TSHRACMSD | |
| SCHEMBL29852167 | 0.82 | KMT2A (0.50) | P2RX7KMT2AJUNNFKB1NFKB2 | |
| SCHEMBL17823660 | 0.82 | KCNJ1 (0.40) | P2RX7ALDH1A1KMT2AJUNNFKB1 | |
| SCHEMBL3346012 | 0.79 | KDM4E (0.43) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL698657 | 0.79 | KDM4E (0.52) | ASPHKDM4EALOX15TSHRACMSD | |
| SCHEMBL14903857 | 0.77 | JUN (0.41) | KDM4EP2RX7ALDH1A1JUNNFKB1 | |
| SCHEMBL31312414 | 0.77 | MAPK1 (0.43) | KDM4EALDH1A1KMT2ANOTUML3MBTL1 | |
| SCHEMBL3295796 | 0.76 | TRPV4 (0.48) | KDM4ETSHRP2RX7ALDH1A1KMT2A | |
| Hydrazine SCHEMBL23496608 | 0.74 | KDM4E (0.48) | ASPHKDM4EALOX15TSHRACMSD | |
| SCHEMBL1111621 | 0.73 | CYP1A2 (0.49) | KDM4ETSHRALDH1A1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727922-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12539295-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20250206729-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2025-06-26 | — | — | US | disclosed |
| WO-2025137105-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2024263460-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20240131016-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-04-25 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| EP-4251622-A1 | AROMATIC BRIDGED RING AMIDE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2023-10-04 | — | — | EP | disclosed |
| US-20230286929-A1 | AROMATIC BRIDGED RING AMIDE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-8377941-B2 | Indoles as modulators of nicotinic acetylcholine receptor subtype alpha-7 | PROXIMAGEN LIMITED (GB) | 2013-02-19 | — | — | US | disclosed |
| US-8377941-B2 | Indoles as modulators of nicotinic acetylcholine receptor subtype alpha-7 | PROXIMAGEN LIMITED (GB) | 2013-02-19 | — | — | US | disclosed |
| US-8377941-B2 | Indoles as modulators of nicotinic acetylcholine receptor subtype alpha-7 | PROXIMAGEN LIMITED (GB) | 2013-02-19 | — | — | US | disclosed |
| EP-2279183-B1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | PROXIMAGEN LTD (GB) | 2012-08-08 | — | — | EP | disclosed |
| US-20110028486-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | GLAXOSMITHKLINE SERVICES UNLIMITED (GB) | 2011-02-03 | — | — | US | disclosed |
| US-20110028486-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | GLAXOSMITHKLINE SERVICES UNLIMITED (GB) | 2011-02-03 | — | — | US | disclosed |
| US-20110028486-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | GLAXOSMITHKLINE SERVICES UNLIMITED (GB) | 2011-02-03 | — | — | US | disclosed |
| EP-2279183-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | Glaxo Group Limited (GB) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009127679-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009127679-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206729-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | BRAF, MAP2K2, MAP2K1 | ASPH 3377/4885KDM4E 3884/4885ALOX15 4833/4885 |
| US-12539295-B2 | IRAK degraders and uses thereof | IRAK2, IRAK4, IRAK3 | ASPH 1707/4885KDM4E 810/4885ALOX15 2544/4885 |
| US-20230286929-A1 | AROMATIC BRIDGED RING AMIDE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP4B1, CYP2E1 | ASPH 103/4885KDM4E 968/4885ALOX15 3714/4885 |
| US-20240131016-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ASPH 640/4885KDM4E 190/4885ALOX15 3105/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ASPH 640/4885KDM4E 190/4885ALOX15 3105/4885 |
| US-20110028486-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | CHRNA7, CHRNA5, CHRNA6 | ASPH 2977/4885KDM4E 2285/4885ALOX15 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.